BillionToOne Reaches Major Achievement with UNITY Tests
UNITY is the only commercially available non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a single maternal blood draw.
BillionToOne, Inc., a molecular diagnostics company committed to creating powerful and accurate tests for everyone, has proudly announced that it has completed one million UNITY prenatal tests. This celebrated milestone showcases the exceptional performance and innovative offerings that have driven BillionToOne's growth, positioning the company as a significant player in the prenatal testing sector.
The UNITY Fetal Risk Screen, powered by BillionToOne's patented Quantitative Counting Template technology, stands as a one-of-a-kind prenatal genetic test. Unlike other tests, it assesses the baby's risk for recessively inherited conditions such as cystic fibrosis, spinal muscular atrophy, and sickle cell disease. Remarkably, it achieves this without the need for a male partner's sample or any invasive procedures, making it a groundbreaking development in prenatal care.
“Surpassing 1 million UNITY tests within just five years is not only a remarkable milestone but also a testament to the transformative power of our technology in enhancing prenatal care,” said Oguzhan Atay, Ph.D., Co-Founder and CEO of BillionToOne. “This year, our annual run-rate has already exceeded 500,000 UNITY tests, showcasing our exponential growth and solidifying UNITY as the new standard in prenatal care. This achievement could not have been realized without our dedicated employees, supportive partners, and trusted healthcare providers.”
As the fastest-growing molecular diagnostics laboratory, BillionToOne has recorded a staggering 100% revenue growth year-over-year in 2024. Reaching this milestone reinforces the company’s commitment to democratizing access to crucial prenatal testing, especially for those communities needing it most.
The revolutionary QCT technology used by BillionToOne is also pivotal in its Northstar Select and Northstar Response assays. These innovative assays are pivotal for therapy selection and monitoring treatment responses, transforming cancer care by enabling precise single-molecule sensitivity and quantification through a non-invasive blood test.
BillionToOne continues to drive accessibility and accuracy in molecular diagnostics, fundamentally reshaping the way prenatal and cancer care is approached.
About BillionToOne
Headquartered in Menlo Park, BillionToOne is dedicated to enhancing the field of molecular diagnostics, making them more accurate and efficient for everyone. Its patented Quantitative Counting Templates (QCT) technology uniquely allows counting of DNA molecules at a single-molecule level as early as nine weeks of gestation.
Frequently Asked Questions
What milestone has BillionToOne achieved recently?
BillionToOne has recently celebrated conducting one million UNITY prenatal tests.
What is the significance of the UNITY tests?
UNITY tests provide a non-invasive method to assess fetal risks for various conditions from a single maternal blood draw, enhancing prenatal care.
How does BillionToOne differentiate itself in the market?
The company utilizes patented Quantitative Counting Template technology, offering unique prenatal genetic tests that do not require invasive procedures.
What are the applications of BillionToOne's technology?
The technology is also utilized in cancer diagnostics through assays that assist in therapy selection and monitoring treatment responses.
How can I learn more about BillionToOne's offerings?
For further information regarding their tests and technology, you can visit their official website.
